Ascelia Pharma AB (publ) (STO:ACE)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.695
-0.105 (-2.19%)
Aug 1, 2025, 5:29 PM CET
-2.19%
Market Cap556.92M
Revenue (ttm)n/a
Net Income (ttm)-85.07M
Shares Out116.03M
EPS (ttm)-1.22
PE Ration/a
Forward PE45.37
Dividendn/a
Ex-Dividend Daten/a
Volume674,154
Average Volume995,094
Open4.820
Previous Close4.800
Day's Range4.610 - 4.820
52-Week Range2.000 - 5.000
Beta1.06
RSI60.74
Earnings DateAug 21, 2025

About United States Steel

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.